You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

ORAPRED ODT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Orapred Odt, and what generic alternatives are available?

Orapred Odt is a drug marketed by Concordia Pharms Inc and is included in one NDA.

The generic ingredient in ORAPRED ODT is prednisolone sodium phosphate. There are eighty-eight drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the prednisolone sodium phosphate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Orapred Odt

A generic version of ORAPRED ODT was approved as prednisolone sodium phosphate by BAUSCH AND LOMB on July 29th, 1994.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ORAPRED ODT?
  • What are the global sales for ORAPRED ODT?
  • What is Average Wholesale Price for ORAPRED ODT?
Drug patent expirations by year for ORAPRED ODT
Drug Prices for ORAPRED ODT

See drug prices for ORAPRED ODT

Drug Sales Revenue Trends for ORAPRED ODT

See drug sales revenues for ORAPRED ODT

Recent Clinical Trials for ORAPRED ODT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Chulalongkorn UniversityN/A
University of FloridaPhase 4
Winston Chamberlain, MD, PhDPhase 4

See all ORAPRED ODT clinical trials

Pharmacology for ORAPRED ODT
Paragraph IV (Patent) Challenges for ORAPRED ODT
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ORAPRED ODT Orally Disintegrating Tablets prednisolone sodium phosphate 10 mg, 15 mg and 30 mg 021959 1 2010-07-22

US Patents and Regulatory Information for ORAPRED ODT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Concordia Pharms Inc ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-001 Jun 1, 2006 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Concordia Pharms Inc ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-002 Jun 1, 2006 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Concordia Pharms Inc ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-003 Jun 1, 2006 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ORAPRED ODT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Concordia Pharms Inc ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-003 Jun 1, 2006 ⤷  Sign Up ⤷  Sign Up
Concordia Pharms Inc ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-001 Jun 1, 2006 ⤷  Sign Up ⤷  Sign Up
Concordia Pharms Inc ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-001 Jun 1, 2006 ⤷  Sign Up ⤷  Sign Up
Concordia Pharms Inc ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-002 Jun 1, 2006 ⤷  Sign Up ⤷  Sign Up
Concordia Pharms Inc ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-002 Jun 1, 2006 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for ORAPRED ODT

See the table below for patents covering ORAPRED ODT around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 0494972 PRESENTATION SOUS FORME EFFERVESCENTE D'UN MEDICAMENT A USAGE PEDIATRIQUE (EFFERVESCENT DOSAGE FORM AND METHOD OF ADMINISTERING SAME) ⤷  Sign Up
European Patent Office 1133282 ⤷  Sign Up
Germany 69029273 ⤷  Sign Up
Denmark 0494972 ⤷  Sign Up
Australia 646232 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.